Lyubov Slashcheva, Rick Rader, MD, and Stephen B. Sulkes, MD
Designation of people with intellectual and developmental disabilities as a medically underserved population would not solve problems of access to care.
AMA J Ethics. 2016;18(4):422-429. doi:
10.1001/journalofethics.2016.18.4.pfor1-1604.
Tina K. Sacks, PhD, Katie Savin, MSW, and Quenette L. Walton, PhD, LCSW
Would you question health decisions made by a 37-year old Black woman whose great-grandfather died in the US Public Health Service Syphilis Study at Tuskegee?
AMA J Ethics. 2021;23(2):E183-188. doi:
10.1001/amajethics.2021.183.
Clinicians with obligations to patients and to organizations often assess patients in law enforcement for both therapeutic and nontherapeutic purposes.
AMA J Ethics. 2022;24(2):E111-119. doi:
10.1001/amajethics.2022.111.
Bjorg Thorsteinsdottir, MD, Annika Beck, and Jon C. Tilburt, MD, MPH
Good clinicians understand why a patient is asking for a test or treatment, and their skillful counseling can often stem the tide of requests for marginally beneficial tests and procedures.
AMA J Ethics. 2015;17(11):1028-1034. doi:
10.1001/journalofethics.2015.17.11.ecas2-1511.
Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
Felix Gonzalez-Torres' and Gregg Bordowitz’s works express their experiences of living through a pandemic and subsequent social change and draw out key human rights themes.
AMA J Ethics. 2020;22(9):E821-829. doi:
10.1001/amajethics.2020.821.